AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25933490 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil group (FO) - 3 g/d of fish oil ω‐3 fatty acids (10 capsules)
Number of subjects: 102
Study 25933490 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra virgin olive oil group (OO) - 10 mL/d of extra virgin olive oil at lunch and dinner
Number of subjects: 102
Study 25933490 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil and extra virgin olive oil group (FOO) - 3 g/d of fish oil ω‐3 fatty acids and 10 mL/d of extra virgin olive oil
Number of subjects: 102
Study 25933490 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) - instructed to maintain their usual diet
Number of subjects: 102
Study 23329628 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 19)
Number of subjects: 40
Study 23329628 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 21)
Number of subjects: 40
Study 22151987 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus etoposide (Arm I)
Number of subjects: 65
Study 22151987 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin plus paclitaxel (Arm II)
Number of subjects: 65
Study 19321022 — intervention group
Group type: EXPERIMENTAL
Intervention: General Psychiatric Management (GPM)
Number of subjects: 50
Study 19321022 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotropic medications (mean number prescribed: 2.3)
Number of subjects: 50
Study 16501729 — intervention group
Group type: EXPERIMENTAL
Intervention: Bednet protection from birth (group A)
Number of subjects: 3387
Study 16501729 — intervention group
Group type: COMPARATOR
Intervention: Bednet protection from age 6 months (group B)
Number of subjects: 3387
Study 12031825 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g n-3 PUFA for 14 days
Number of subjects: 18
Study 12031825 — intervention group
Group type: COMPARATOR
Intervention: 100 mg ASA (intravenous)
Number of subjects: 18
Study 12031825 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFA and ASA combination
Number of subjects: 18
Study 10435398 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose isradipine (0.21 mg/kg orally)
Number of subjects: 18
Study 10435398 — intervention group
Group type: COMPARATOR
Intervention: Low-dose d-methamphetamine (0.21 mg/kg orally)
Number of subjects: 18
Study 10435398 — intervention group
Group type: COMPARATOR
Intervention: High-dose d-methamphetamine (0.42 mg/kg orally)
Number of subjects: 18
Study 10435398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 7594092 — intervention group
Group type: EXPERIMENTAL
Intervention: Bypass surgery
Number of subjects: 214
Study 7594092 — intervention group
Group type: EXPERIMENTAL
Intervention: Angioplasty
Number of subjects: 214
Study 7594092 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapy
Number of subjects: 214
Study 2138405 — intervention group
Group type: EXPERIMENTAL
Intervention: Home‐Help Group (frequent contacts from diet leader)
Number of subjects: 0
Study 2138405 — intervention group
Group type: COMPARATOR
Intervention: No Help Group (no caretaker-directed communications)
Number of subjects: 0
Study 371034 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicitropeptide
Number of subjects: 106
Study 371034 — intervention group
Group type: COMPARATOR
Intervention: Antacid (Maalox)
Number of subjects: 106
Study 371034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 6137694 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligoantigenic diet
Number of subjects: 88
Study 30756527 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg/d ifenprodil
Number of subjects: 0
Study 30756527 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30756527 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg/d ifenprodil
Number of subjects: 0
Study 29576595 — intervention group
Group type: EXPERIMENTAL
Intervention: Enriched circulating endothelial progenitor cells (ECEPCs) injected into the gastrocnemius of the affected limb.
Number of subjects: 40
Study 29576595 — intervention group
Group type: COMPARATOR
Intervention: Bone marrow mononuclear cells (BM‐MNC) injected into the gastrocnemius of the affected limb.
Number of subjects: 40
Study 26511777 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 127
Study 26511777 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study 25304219 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% homatropine hydrobromide
Number of subjects: 14
Study 25304219 — intervention group
Group type: COMPARATOR
Intervention: 2.5% phenylephrine hydrochloride
Number of subjects: 14
Study 25304219 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.3% hydroxypropyl methylcellulose)
Number of subjects: 14
Study 22176867 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinflunine (VFL) therapy
Number of subjects: 179
Study 20007944 — intervention group
Group type: EXPERIMENTAL
Intervention: Prandial insulin aspart (IAsp) administered immediately before each meal
Number of subjects: 322
Study 20007944 — intervention group
Group type: COMPARATOR
Intervention: Human insulin administered 30 min before each meal
Number of subjects: 322
Study 17612657 — intervention group
Group type: COMPARATOR
Intervention: Intracoronary saline solution
Number of subjects: 75
Study 17612657 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine (12 microg/bolus)
Number of subjects: 75
Study 17612657 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of adenosine (12 microg/bolus) and sodium nitroprusside (50 microg/bolus)
Number of subjects: 75
Study 16035081 — intervention group
Group type: EXPERIMENTAL
Intervention: rFVIIa (20, 40, or 80 microg/kg)
Number of subjects: 83
Study 16035081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 11926599 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at four local points around the knee and one distal point
Number of subjects: 0
Study 11926599 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 0
Study 10890777 — intervention group
Group type: EXPERIMENTAL
Intervention: AAV-CFTR
Number of subjects: 10
Study 7890239 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/kg ALA
Number of subjects: 18
Study 7890239 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg/kg ALA
Number of subjects: 18
Study 7890239 — intervention group
Group type: EXPERIMENTAL
Intervention: Red laser light (628 nm) treatment after ALA administration
Number of subjects: 18
Study 7890239 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 18
Study 1835398 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate (1.6g orally daily for 18 months)
Number of subjects: 0
Study 1835398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6119766 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine 50 mg twice a day
Number of subjects: 9
Study 6119766 — intervention group
Group type: EXPERIMENTAL
Intervention: L-hyoscyamine 0.6 mg twice a day
Number of subjects: 9
Study 6119766 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 31422845 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly developed computerized intervention aimed at decreasing perceived burdensomeness and thwarted belongingness
Number of subjects: 46
Study 31422845 — intervention group
Group type: COMPARATOR
Intervention: Repeated contact control condition
Number of subjects: 46
Study 27600941 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Recovery Cognitive Behavioural Therapy (SRCBT)
Number of subjects: 0
Study 27600941 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study 27600941 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SRCBT and Treatment as usual
Number of subjects: 0
Study 26813869 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional height‐based balloon reference sizing (HBRS)
Number of subjects: 128
Study 26813869 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic measurement of the diastolic inter‐commissural diameter (EBRS)
Number of subjects: 128
Study 24359938 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ibuprofen (initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 hours)
Number of subjects: 90
Study 24359938 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral paracetamol (15 mg/kg every 6 hours for 3 days)
Number of subjects: 90
Study 24359938 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral paracetamol
Number of subjects: 90
Study 24359938 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ibuprofen
Number of subjects: 90
Study 21292439 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice therapy after BTX‐A injection
Number of subjects: 31
Study 21292439 — intervention group
Group type: COMPARATOR
Intervention: BTX‐A injection
Number of subjects: 31
Study 21292439 — intervention group
Group type: COMPARATOR
Intervention: Sham voice therapy after BTX‐A injection
Number of subjects: 31
Study 19057384 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed-model prediction
Number of subjects: 509
Study 19057384 — intervention group
Group type: COMPARATOR
Intervention: Individual-level estimates
Number of subjects: 509
Study 19057384 — intervention group
Group type: COMPARATOR
Intervention: Group-level estimates
Number of subjects: 509
Study 17996121 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether plus lumefantrine (AL)
Number of subjects: 157
Study 17996121 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate plus amodiaquine (AS+AQ)
Number of subjects: 157
Study 17996121 — intervention group
Group type: COMPARATOR
Intervention: Sulphadoxine-pyrimethamine (SP)
Number of subjects: 157
Study 16382596 — intervention group
Group type: EXPERIMENTAL
Intervention: iBond GI (Heraeus Kulzer, Inc)
Number of subjects: 0
Study 16382596 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper Prompt L-Pop (3M ESPE)
Number of subjects: 0
Study 16382596 — intervention group
Group type: EXPERIMENTAL
Intervention: Xeno III (Caulk/Dentsply)
Number of subjects: 0
Study 16382596 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophobic resin layer added to self-etching adhesives
Number of subjects: 0
Study 16382596 — intervention group
Group type: COMPARATOR
Intervention: UniFil Bond (GC America)
Number of subjects: 0
Study 14647791 — intervention group
Group type: COMPARATOR
Intervention: Healthy carriers
Number of subjects: 911
Study 14647791 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with pneumonia
Number of subjects: 911
Study 14647791 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 911
Study 9709956 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human IGF-I (rhIGF-I; 3 microg/kg-h)
Number of subjects: 11
Study 9709956 — intervention group
Group type: COMPARATOR
Intervention: saline (control)
Number of subjects: 11
Study 7597021 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion activities (nutrition programs, smoking control programs)
Number of subjects: 20801
Study 7597021 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary habits
Number of subjects: 20801
Study 7597021 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking prevalence
Number of subjects: 20801
Study 7597021 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental support for dietary behavior change
Number of subjects: 20801
Study 7597021 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived support for smoking cessation
Number of subjects: 20801
Study 2215986 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane (0.8% end-tidal) with atracurium (0.35 mg/kg)
Number of subjects: 32
Study 2215986 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (1% end-tidal) with atracurium (0.35 mg/kg)
Number of subjects: 32
Study 626731 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed oxytocin infusion (infused for one minute every ten minutes using a modified Cardiff Infusion System Mark III)
Number of subjects: 28
Study 626731 — intervention group
Group type: COMPARATOR
Intervention: Continuous oxytocin infusion
Number of subjects: 28
Study 30261783 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycaemic index diet in pregnancy
Number of subjects: 265
Study 31048449 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated medical assessment and surgical repair (goal within 6 h)
Number of subjects: 3000
Study 31048449 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 3000
Study 28973362 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy followed by allo‐HSCT (HSCT group)
Number of subjects: 96
Study 28973362 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (chemotherapy group)
Number of subjects: 96
Study 28973362 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional chemotherapy (adult regimen)
Number of subjects: 96
Study 28973362 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric regimens
Number of subjects: 96
Study 28973362 — intervention group
Group type: EXPERIMENTAL
Intervention: High WBC count and CD20 positivity
Number of subjects: 96
Study 28973362 — intervention group
Group type: EXPERIMENTAL
Intervention: Low WBC count and absence of CD20
Number of subjects: 96
Study 25764173 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral malaria (CM)
Number of subjects: 45
Study 23106093 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy (2 hours of structured exercise weekly for 6 months)
Number of subjects: 63
Study 23106093 — intervention group
Group type: COMPARATOR
Intervention: Occupational therapy (2 hours weekly for 6 months)
Number of subjects: 63
Study 21571547 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI + SET
Number of subjects: 70
Study 21571547 — intervention group
Group type: COMPARATOR
Intervention: PVI alone
Number of subjects: 70
Study 18844760 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-minute rest period
Number of subjects: 549
Study 18844760 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive drug treatment (perindopril, amlodipine, or labetalol)
Number of subjects: 549
Study 16140433 — intervention group
Group type: EXPERIMENTAL
Intervention: M01ZH09 vaccine at 5 x 10(9) CFU
Number of subjects: 60
Study 16140433 — intervention group
Group type: EXPERIMENTAL
Intervention: M01ZH09 vaccine at 5 x 10(8) CFU
Number of subjects: 60
Study 16140433 — intervention group
Group type: EXPERIMENTAL
Intervention: M01ZH09 vaccine at 5 x 10(7) CFU
Number of subjects: 60
Study 16140433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 13680163 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol (total dose 320 mg)
Number of subjects: 10
Study 13680163 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (total dose 30 mg)
Number of subjects: 10
Study 13680163 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 10897370 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (150-200 micrograms/kg)
Number of subjects: 1425
Study 10897370 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Ivermectin and Albendazole (400 mg)
Number of subjects: 1425
Study 10897370 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (400 mg)
Number of subjects: 1425
Study 10897370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1425
Study 8775253 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot goserelin acetate, 3.6 mg, subcutaneously at 4-weekly intervals
Number of subjects: 72
Study 8775253 — intervention group
Group type: COMPARATOR
Intervention: Danazol, 600 mg/day
Number of subjects: 72
Study 1486391 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous epirubicin 90 mg/m2 every 28 days
Number of subjects: 29
Study 6419958 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 174
Study 6419958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study 31470815 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented Prescribed Exercise Program (APEP) - additional exercise sessions (20-30 min, 4-5 times/week)
Number of subjects: 35
Study 31470815 — intervention group
Group type: COMPARATOR
Intervention: Usual care (including physiotherapy)
Number of subjects: 35
Study 29893144 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-dependent therapies (Strategy A)
Number of subjects: 47
Study 29893144 — intervention group
Group type: COMPARATOR
Intervention: Glucose-independent therapies (Strategy B)
Number of subjects: 47
Study 27378704 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 148
Study 27378704 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 148
Study 27378704 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole
Number of subjects: 148
Study 25956287 — intervention group
Group type: EXPERIMENTAL
Intervention: Coumarin anticoagulants
Number of subjects: 847
Study 23550910 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine digluconate (CHX) adhesive
Number of subjects: 120
Study 23550910 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0% chlorhexidine digluconate (CHX) therapeutic primer
Number of subjects: 120
Study 23550910 — intervention group
Group type: COMPARATOR
Intervention: Control group without CHX
Number of subjects: 120
Study 21266513 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated vaccination schedule (10 μg HBvaxPRO, 0-1-3 week schedule)
Number of subjects: 761
Study 21266513 — intervention group
Group type: COMPARATOR
Intervention: Standard vaccination schedule (10 μg HBvaxPRO, 0-4-24 week schedule)
Number of subjects: 761
Study 21266513 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated vaccination schedule
Number of subjects: 761
Study 19295936 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of restaurants in census tracts
Number of subjects: 132
Study 19295936 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of other food service places in census tracts
Number of subjects: 132
Study 19295936 — intervention group
Group type: COMPARATOR
Intervention: Presence of convenience stores and lower neighborhood SES
Number of subjects: 132
Study 16825691 — intervention group
Group type: EXPERIMENTAL
Intervention: Drink B (CPP-enriched preparation, 1.7 g CPP, 400 mg Ca as calcium lactate)
Number of subjects: 15
Study 16825691 — intervention group
Group type: EXPERIMENTAL
Intervention: Drink C (CPP-enriched preparation, 1.7 g CPP, 400 mg Ca as calcium lactate)
Number of subjects: 15
Study 16825691 — intervention group
Group type: COMPARATOR
Intervention: Drink A (calcium lactate drink, 400 mg Ca as lactate)
Number of subjects: 15
Study 12860542 — intervention group
Group type: EXPERIMENTAL
Intervention: Trapezius muscle activity in athletes with impingement
Number of subjects: 69
Study 12860542 — intervention group
Group type: COMPARATOR
Intervention: Trapezius muscle activity in control subjects (no impingement)
Number of subjects: 69
Study 10833865 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 9106276 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual cues at four locations occurring simultaneously
Number of subjects: 0
Study 9106276 — intervention group
Group type: EXPERIMENTAL
Intervention: Adding a visual alerting signal to an auditory signal
Number of subjects: 0
Study 9106276 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory signal used to modulate alertness level during a covert orienting task
Number of subjects: 0
Study 9106276 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice task
Number of subjects: 0
Study 7845645 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybuprocaine
Number of subjects: 212
Study 7845645 — intervention group
Group type: EXPERIMENTAL
Intervention: Betoxycaine
Number of subjects: 212
Study 7845645 — intervention group
Group type: COMPARATOR
Intervention: Metipranolol
Number of subjects: 212
Study 7845645 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin suspension
Number of subjects: 212
Study 2842842 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg glucagon
Number of subjects: 246
Study 29304325 — intervention group
Group type: EXPERIMENTAL
Intervention: L-PRF
Number of subjects: 60
Study 29304325 — intervention group
Group type: EXPERIMENTAL
Intervention: L-PRF-plus-HA
Number of subjects: 60
Study 29304325 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study 29304325 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60
Study 28070894 — intervention group
Group type: EXPERIMENTAL
Intervention: TAS-102 tablets (60 mg; 3 × 20-mg tablets)
Number of subjects: 46
Study 28070894 — intervention group
Group type: COMPARATOR
Intervention: TAS-102 oral solution (60 mg)
Number of subjects: 46
Study 25824212 — intervention group
Group type: EXPERIMENTAL
Intervention: Benznidazole (BNZ) at 2.5 mg/kg of body weight/12 h for 60 days
Number of subjects: 39
Study 25133413 — intervention group
Group type: EXPERIMENTAL
Intervention: theory‐based social‐cognitive intervention
Number of subjects: 280
Study 25133413 — intervention group
Group type: COMPARATOR
Intervention: passive waiting‐list control group
Number of subjects: 280
Study 25133413 — intervention group
Group type: COMPARATOR
Intervention: active control intervention designed to motivate physical activity
Number of subjects: 280
Study 22572644 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat yogurt
Number of subjects: 11
Study 22572644 — intervention group
Group type: COMPARATOR
Intervention: Low-fat yogurt
Number of subjects: 11
Study 20981000 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-0249 50 mg
Number of subjects: 24
Study 20981000 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-0249 10 mg
Number of subjects: 24
Study 20981000 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 200 mg
Number of subjects: 24
Study 20981000 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 18401299 — intervention group
Group type: EXPERIMENTAL
Intervention: Two eyedrops of cyclopentolate 0.5% at a 10-min interval
Number of subjects: 36
Study 18401299 — intervention group
Group type: COMPARATOR
Intervention: Three eyedrops of cyclopentolate 0.5% at a 5-min interval
Number of subjects: 36
Study 18401299 — intervention group
Group type: EXPERIMENTAL
Intervention: Both protocols (two drops and three drops)
Number of subjects: 36
Study 15845499 — intervention group
Group type: EXPERIMENTAL
Intervention: One dose of tetravalent polysaccharide vaccine for children >/=24 months old
Number of subjects: 0